Dermatology

This site is intended for healthcare professionals only

Login Register

MD Brand Connect
Webinars
Vaccine Hub
MDTV
Fact Check
Health Dialogues

Medical News & Guidelines
Health news
Fact Check
AYUSH
State News
Medical Education
Industry
MDTV

This site is intended for healthcare professionals only

Login Register

LoginRegister

Home
Medical news & Guidelines
Health news
Fact Check
AYUSH
State News
Medical Education
Industry

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Home

Ruchika Sharma

Articles By : Ruchika Sharma

Cipla gets USFDA nod for Dimethyl Fumarate DR Capsules to treat multiple sclerosis

Ruchika Sharma27 Sept 2020 10:00 AM IST

Mumbai: Drugmaker, Cipla Limited, has recently announced that the company has received final approval for its Abbreviated New Drug Application...

Phase-3 trial of COVAXIN to begin in Lucknow, Gorakhpur from October

Ruchika Sharma27 Sept 2020 9:45 AM IST

Lucknow: The Uttar Pradesh government on Thursday announced that phase-3 trial of the coronavirus vaccine 'COVAXIN' will start in Lucknow and...

GSK, Sanofi ink Covid-19 vaccine supply deal with Canada

Ruchika Sharma27 Sept 2020 9:15 AM IST

Paris and London: Sanofi and GSK have recently announced that they have signed agreements with the Government of Canada for the supply of up to...

Biocon employee penalized by SEBI for violating insider trading norms

Ruchika Sharma26 Sept 2020 4:09 PM IST

Biocon Ltd's employee Girija Kelath violated the Prohibition of Insider Trading (PIT) Regulations by trading in the shares of Biocon during the...

Hetero unveils Favivir 800/200 priced at Rs 2640 per pack

Ruchika Sharma26 Sept 2020 12:15 PM IST

"The launch of 'Favivir 800/2000' is aimed at enhancing patients' adherence to treatment regimen by reducing the number of pills they are required to...

Panacea Biotec DengiAll vaccine completes phase 1/2 study

Ruchika Sharma26 Sept 2020 11:45 AM IST

DengiAll is a single-dose live-attenuated tetravalent vaccine.

Zydus Cadila gets USFDA nod for multiple sclerosis drug

Ruchika Sharma26 Sept 2020 10:00 AM IST

Ahmedabad: Drugmaker, Zydus Cadila, has recently announced that the company has received final approval from the U.S. Food and Drug...

ICAR-IVRI tech acquired by Hester to develop brucella vaccine for cattle

Ruchika Sharma26 Sept 2020 9:00 AM IST

New Delhi: Hester Bioscience Ltd on Wednesday said it has acquired a technology from the government''s research body ICAR-IVRI to develop a new...

Pharma giants to inform risk of COVID vaccine-associated Enhanced Respiratory Disease: DCGI

Ruchika Sharma25 Sept 2020 1:46 PM IST

Dr Bhargava answered in view of the draft guidelines published by the Central Drugs Standard Control Organisation (CDSCO) for the development of a...

Pharma firms to boost export to come out unscathed from Covid-19: Rating agency CRISIL

Ruchika Sharma25 Sept 2020 1:00 PM IST

Mumbai: Higher exports will help the Indian pharmaceutical sector come out "unscathed" from the coronavirus pandemic and deliver a marginally lower 9...

Zydus Cadila anti-cancer drug Palbociclib gets tentative USFDA nod

Ruchika Sharma25 Sept 2020 11:45 AM IST

Palbociclib is an anti-cancer medicine that interferes with the growth and spread of cancer cells in the body.

Sanofi not involved in COVID-19 human challenge trial: Spokesman

Ruchika Sharma25 Sept 2020 9:15 AM IST

Paris: Sanofi is not involved in the COVID-19 human challenge trials reported to be launched in Britain and its potential vaccines are not being used...

Powered By: Hocalwire

X

We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok